Levocetirizine for the complex treatment of allergic dermatitis
DOI: 10.32364/2587-6821-2022-6-2-105-109
L.S. Kruglova, A.L. Bakulev
Central State Medical Academy, Moscow, Russian Federation
Allergic dermatitis is one of the most common skin diseases. Pathogenically, allergic dermatitis is a delayed hypersensitivity reaction. Allergic dermatitis is provoked by various agents that penetrate the skin. More than 3,500 potential contact allergens were described. The immune response in allergic dermatitis is conventionally characterized by two phases, afferent and efferent. Treatment for allergic dermatitis includes topical and systemic therapies (antihistamines) and physiotherapy. The authors address their experience with the management of patients with allergic dermatitis. Twenty-eight patients were enrolled. The predominant clinical manifestations were erythematous lesions, infiltration, and vesicles associated with itching. All patients received levocetirizine 5 mg daily and topical steroids (methylprednisolone acetate propionate) for 10–15 days. After 2 weeks, this treatment resulted in complete symptom relief. Complex treatment for allergic dermatitis (levocet irizine 5 mg daily and topical steroids) is effective against all clinical symptoms, including itching.
Keywords: allergic dermatitis, treatment, antihistamines, levocetirizine, visual analogue scale, Dermatology Life Quality Index.
For citation: Kruglova L.S., Bakulev A.L. Levocetirizine for the complex treatment of allergic dermatitis. Russian Medical Inquiry. 2022;6(2):105–109 (in Russ.). DOI: 10.32364/2587-6821-2022-6-2-105-109.
About the authors:
Larisa S. Kruglova — Dr. Sc. (Med.), Professor, Head of the Department of Dermatovenerology and Cosmetology, Vice Rector for Academic Work, Central State Medical Academy; 19, build. 1A, Marshal Timoshenko str., Moscow, 121359, Russian Federation; ORCID iD 0000-0002-5044-5265.
Andrey L. Bakulev — Dr. Sc. (Med.), professor of the Department of Dermatovenerology and Cosmetology, Central State Medical Academy; 19, build. 1A, Marshal Timoshenko str., Moscow, 121359, Russian Federation; ORCID iD 0000-0002-1450-4942.
Contact information: Larisa S. Kruglova, e-mail: kruglovals@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 03.02.2022.
Revised 01.03.2022.
Accepted 28.03.2022.
2. Hillen U., Grabbe S., Uter W. Patch test results in patients with scalp dermatitis: analysis of data of the Information Network of Departments of Dermatology. Contact Dermatitis. 2007;56(2):87–93. doi: 10.1111/j.1600–0536.2007.01000.x.
3. Gober M.D., Gaspari A.A. Allergic contact dermatitis. Curr Dir Autoimmun. 2008;10:1–26. doi: 10.1159/000131410.
4. Kaplan D.H., Igyártó B.Z., Gaspari A.A. Early immune events in the induction of allergic contact dermatitis. Nat Rev Immunol. 2012;12(2):114–124. doi: 10.1038/nri3150.
5. Martin S.F. New concepts in cutaneous allergy. Contact Dermatitis. 2015;72(1):2–10. doi: 10.1111/cod.12311.
6. Vocanson M., Hennino A., Rozières A. et al. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy. 2009;64(12):1699–1714. doi: 10.1111/j.1398-9995.2009.02082.x.
7. Nassau S., Fonacier L. Allergic Contact Dermatitis. Med Clin North Am. 2020;104(1):61–76. doi: 10.1016/j.mcna.2019.08.012.
8. Паттерсон Р., Грэммер Л.К., Гринбергер П.А., ред. Аллергические болезни: диагностика и лечение. Пер. с англ. М.: ГЭОТАР-МЕДИЦИНА; 2000. [Patterson R., Grammer L.K., Greenberger P.A., eds. Allergic diseases. Diagnosis and managment. Translation from English. M.: GEOTAR- MEDITSINA; 2000 (in Russ.)].
9. Hair P.I., Scott L.J. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs. 2006;66(7):973–996. doi: 10.2165/00003495-200666070-00017.
10. Gillard M., Van Der Perren C., Moguilevsky N. et al. Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol Pharmacol. 2002;61(2):391–399. doi: 10.1124/mol.61.2.391.
11. Benedetti M.S., Plisnier M., Kaise J. et al. Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol. 2001;57(8):571–582. doi: 10.1007/s002280100364.
12. Devillier P., Roche N., Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet. 2008;47(4):217–230. doi: 10.2165/00003088-200847040-00001.
13. Jáuregui I., Ferrer M., Montoro J. et al. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol. 2007;17 Suppl 2:41–52.
14. Del Cuvillo A., Mullol J., Bartra J. et al. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol. 2006;16 Suppl 1:3–12.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
